Literature DB >> 11148546

Laboratory evaluation of urea cycle disorders.

R D Steiner1, S D Cederbaum.   

Abstract

The urea cycle disorders (UCDs) represent a group of inherited metabolic diseases with hyperammonemia as the primary laboratory abnormality. Affected individuals may become comatose or die if not treated rapidly. Diagnosis of a UCD requires a high index of suspicion and judicious use of the laboratory. It is important to rule out other conditions causing hyperammonemia that may require different treatment. The astute clinician may suspect a specific UCD in the appropriate clinical setting, but only laboratory results can confirm a specific diagnosis. The importance of the laboratory in helping the clinician to differentiate among various causes of hyperammonemia, in confirming a specific UCD, in carrier testing, and in prenatal diagnostic testing is highlighted in this review.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11148546     DOI: 10.1067/mpd.2001.111833

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

1.  On the Creation, Utility and Sustaining of Rare Diseases Research Networks: Lessons learned from the Urea Cycle Disorders Consortium, the Japanese Urea Cycle Disorders Consortium and the European Registry and Network for Intoxication Type Metabolic Diseases.

Authors:  Marshall L Summar; Fumio Endo; Stefan Kölker
Journal:  Mol Genet Metab       Date:  2014 Sep-Oct       Impact factor: 4.797

2.  Hyperammonaemia in a child with distal renal tubular acidosis.

Authors:  D Seracini; G M Poggi; I Pela
Journal:  Pediatr Nephrol       Date:  2005-08-18       Impact factor: 3.714

3.  An unusual clinical and biochemical presentation of ornithine transcarbamylase deficiency in a male patient.

Authors:  A B Burlina; A Peduto; A Di Palma; A Bellizzi; D Sperlì; A Morrone; A P Burlina
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

4.  Urea Cycle Disorders.

Authors:  Soledad Kleppe; Asad Mian; Brendan Lee
Journal:  Curr Treat Options Neurol       Date:  2003-07       Impact factor: 3.972

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.